Literature DB >> 23674856

ABO blood type, long-standing diabetes, and the risk of pancreatic cancer.

Naoto Egawa1, Yingsong Lin, Taku Tabata, Sawako Kuruma, Seiichi Hara, Ken Kubota, Terumi Kamisawa.   

Abstract

AIM: To retrospectively study pancreatic cancer patients with respect to their ABO blood type and diabetes.
METHODS: Our analysis included a cohort of 1017 patients with pancreatic ductal cancer diagnosed at our hospital in Tokyo. They were divided into two groups: 114 patients with long-standing type 2 diabetes (DM group, defined as diabetes lasting for at least three years before the diagnosis of pancreatic cancer) and 903 patients without diabetes (non-DM group). Multivariate analysis was performed to identify factors that are associated with long-standing diabetes. The DM group was further divided into three subgroups according to the duration of diabetes (3-5 years, 5.1-14.9 years, and 15 years or more) and univariate analyses were performed.
RESULTS: Of the 883 pancreatic cancer patients with serologically assessed ABO blood type, 217 (24.6%) had blood type O. Compared with the non-DM group, the DM group had a higher frequency of blood type B [odds ratio (OR) = 2.61, 95%CI: 1.24-5.47; reference group: blood type A]. Moreover, male (OR = 3.17, 95%CI: 1.67-6.06), older than 70 years of age (OR = 2.19, 95%CI: 1.20-3.98) and presence of a family history of diabetes (OR = 6.21, 95%CI: 3.38-11.36) were associated with long-standing type 2 diabetes. The mean ages were 64.8 ± 9.2 years, 67.1 ± 9.8 years, and 71.7 ± 7.0 years in the subgroups with the duration of diabetes, 3-5 years, 5.1-14.9 years, and 15 years or more, respectively (P = 0.007). A comparison of ABO blood type distribution among the subgroups also showed a significant difference (P = 0.03).
CONCLUSION: The association of pancreatic cancer with blood type and duration of diabetes needs to be further examined in prospective studies.

Entities:  

Keywords:  ABO blood type; Diabetes mellitus; Pancreatic cancer; Risk factor; Screening

Mesh:

Substances:

Year:  2013        PMID: 23674856      PMCID: PMC3646145          DOI: 10.3748/wjg.v19.i16.2537

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  26 in total

1.  Statistical studies on the correlation between the ABO-blood groups and some diseases.

Authors:  H MONIWA
Journal:  Tohoku J Exp Med       Date:  1960-10-25       Impact factor: 1.848

2.  Blood groups and susceptibility to disease: a review.

Authors:  J A F ROBERTS
Journal:  Br J Prev Soc Med       Date:  1957-07

Review 3.  Role of inflammation in pancreatic carcinogenesis and the implications for future therapy.

Authors:  G Garcea; A R Dennison; W P Steward; D P Berry
Journal:  Pancreatology       Date:  2005-08-16       Impact factor: 3.996

4.  Relationship between serum tumor necrosis factor-alpha and insulin resistance in obese men with Type 2 diabetes mellitus.

Authors:  Y Mishima; A Kuyama; A Tada; K Takahashi; T Ishioka; M Kibata
Journal:  Diabetes Res Clin Pract       Date:  2001-05       Impact factor: 5.602

5.  The distribution of the ABO blood groups in Japan.

Authors:  Y Fujita; M Tanimura; K Tanaka
Journal:  Jinrui Idengaku Zasshi       Date:  1978-06

6.  Circulating levels of endothelial adhesion molecules and risk of diabetes in an ethnically diverse cohort of women.

Authors:  Yiqing Song; JoAnn E Manson; Lesley Tinker; Nader Rifai; Nancy R Cook; Frank B Hu; Gokhan S Hotamisligil; Paul M Ridker; Beatriz L Rodriguez; Karen L Margolis; Albert Oberman; Simin Liu
Journal:  Diabetes       Date:  2007-03-27       Impact factor: 9.461

7.  Fasting serum glucose level and cancer risk in Korean men and women.

Authors:  Sun Ha Jee; Heechoul Ohrr; Jae Woong Sull; Ji Eun Yun; Min Ji; Jonathan M Samet
Journal:  JAMA       Date:  2005-01-12       Impact factor: 56.272

8.  Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer.

Authors:  Suresh T Chari; Cynthia L Leibson; Kari G Rabe; Lawrence J Timmons; Jeanine Ransom; Mariza de Andrade; Gloria M Petersen
Journal:  Gastroenterology       Date:  2007-10-26       Impact factor: 22.682

9.  ABO blood group and the risk of hepatocellular carcinoma: a case-control study in patients with chronic hepatitis B.

Authors:  Qiang Li; Cui-Hua Yu; Jin-Hong Yu; Li Liu; Shuang-Shuang Xie; Wen-Wen Li; Xia Yang; Wen-Bo Fan; Zhong-Tao Gai; Shi-Jun Chen; Naoya Kato
Journal:  PLoS One       Date:  2012-01-03       Impact factor: 3.240

10.  Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies.

Authors:  R Huxley; A Ansary-Moghaddam; A Berrington de González; F Barzi; M Woodward
Journal:  Br J Cancer       Date:  2005-06-06       Impact factor: 7.640

View more
  7 in total

1.  The ABO blood group predicts survival in esophageal squamous cell carcinoma in patients who ever smoked: a retrospective study from China.

Authors:  Peng Sun; Cui Chen; Fei Zhang; Xin An; Xiu-Yue Li; Yu-Hong Li; Zhi-Hua Zhu; Feng-Hua Wang
Journal:  Tumour Biol       Date:  2014-04-27

Review 2.  Pancreatic ductal adenocarcinoma: risk factors, screening, and early detection.

Authors:  Andrew E Becker; Yasmin G Hernandez; Harold Frucht; Aimee L Lucas
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

3.  Distribution of ABO blood groups in the patients with intracranial aneurysm and association of different risk factors with particular blood type.

Authors:  Shyamal Chandra Bir; Papireddy Bollam; Anil Nanda
Journal:  Asian J Neurosurg       Date:  2015 Jul-Sep

4.  Interaction Between Prediabetes and the ABO Blood Types in Predicting Postsurgical Esophageal Squamous Cell Carcinoma-Specific Mortality: The FIESTA Study.

Authors:  Guohui Fan; Dan Hu; Xinran Zhang; Feng Peng; Xiandong Lin; Gang Chen; Binying Liang; Hejun Zhang; Yan Xia; Xiongwei Zheng; Jianzheng Jie; Wenquan Niu
Journal:  Front Oncol       Date:  2018-10-23       Impact factor: 6.244

5.  Serum amylase activity altered by the ABO blood group system in Chinese subjects.

Authors:  You-Fan Peng; Hemant Goyal; Hao Lin; De-Chen Liu; Ling Li
Journal:  J Clin Lab Anal       Date:  2019-04-02       Impact factor: 2.352

6.  CD26 as a Promising Biomarker for Predicting Prognosis in Patients with Pancreatic Tumors.

Authors:  Liang Yan; Xiuyun Tian; Chunxiang Ye; Xiaoya Guan; Bin Dong; Min Zhao; Jianhui Wu; Chunyi Hao
Journal:  Onco Targets Ther       Date:  2020-12-08       Impact factor: 4.147

7.  Trends in Pancreatic Cancer Incidence and Mortality in Lithuania, 1998-2015.

Authors:  Povilas Kavaliauskas; Audrius Dulskas; Inga Kildusiene; Rokas Arlauskas; Rimantas Stukas; Giedre Smailyte
Journal:  Int J Environ Res Public Health       Date:  2022-01-15       Impact factor: 3.390

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.